GlaxoSmithKline plc Sponsored ADR (GSK.US) Belantamab mafodotin has been approved for sale in China.

On April 17th, the website of the National Medical Products Administration (NMPA) indicated that GlaxoSmithKline plc Sponsored ADR (GSK.US) has obtained approval for the marketing of Belantamab mafodotin (Maybelantumab) in China. According to previous priority review information, the approved indication for this drug is for the treatment of relapsed or refractory multiple myeloma in adult patients who have received at least one prior therapy, in combination with bortezomib and dexamethasone. Belantamab mafodotin is a BCMA ADC developed by Seagen (acquired by Pfizer Inc.). In December 2009, GSK reached an agreement with Seagen to obtain the rights for research, development, production, and commercialization of this drug.